Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

SAN FRANCISCO -- Menopause hormone therapy (MHT) was tied to a weight-loss boost in postmenopausal women taking a weight loss ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...